Changes in Beneficial Ownership · 4
Glaukos Corporation
GKOSNYSEEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-03282026_120327.xml
Filing details
- Report period
- 2026-03-25
- Issuer
- GLAUKOS Corp
- Issuer CIK
- 0001192448
- Trading symbol
- GKOS
Reporting owner 1
- Name
- Burns Thomas William
- Reporting owner CIK
- 0001644557
- Relationship
- Director · Officer
- Officer title
- CHAIRMAN & CEO
- Address
- C/O GLAUKOS CORPORATION, ONE GLAUKOS WAY, ALISO VIEJO, CA, 92656
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-03-25 | A · Form 4 | 9,380[F1] | A | 0 | 249,087[F2] | D |
| Common Stock | 2026-03-25 | A · Form 4 | 14,184[F3] | A | 0 | 263,271[F4] | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Stock | 961,285 | I | Through the Burns Family Trust |
| Common Stock | 238,107 | I | Through the Burns Annuity Trust |
| Common Stock | 120,000 | I | Through the Burns Charitable Remainder Trust |
| Common Stock | 100,000 | I | Through the Thomas W. Burns Irrevocable Trust |
| Common Stock | 100,000 | I | Through the Janet M. Burns Irrevocable Trust |
Table key
- I
- Indirect
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 55.18 | 2026-03-25 | A · Form 4 | 18,933[F5] | A | 18,933 | [F6] | 2032-03-24 | Common Stock | 18,933 | 105,195 | D |
| Stock Option (Right to Buy) | 48.46 | 2026-03-25 | A · Form 4 | 110,254[F7] | A | 110,254 | 2026-03-25 | 2033-03-22 | Common Stock | 110,254 | 110,254 | D |
| Stock Option (Right to Buy) | 109.60 | 2026-03-25 | A · Form 4 | 98,474 | A | 98,474 | [F8] | 2036-03-25 | Common Stock | 98,474 | 98,474 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- Represents shares of common stock underlying a portion of an award of restricted stock units previously granted by the Issuer on March 24, 2022, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period. The Compensation, Nominating and Governance Committee of the Issuer's Board of Directors determined on March 25, 2026 that certain of the operational targets had been achieved. The number of shares of common stock reported herein consists of the portion of the award that was earned based upon the achievement of the operational targets. 50% of the number of shares of common stock reported herein will vest and be delivered in March 2026, and the remaining 50% will vest and be delivered in December 2026.↩ 1
- F2
- Includes 68,779 restricted stock units that have not yet vested or been delivered to the Reporting Person.↩ 1
- F3
- Represents shares of common stock underlying a portion of an award of restricted stock units previously granted by the Issuer on March 14, 2024, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period. The Compensation, Nominating and Governance Committee of the Issuer's Board of Directors determined on March 25, 2026 that certain of the operational targets had been achieved. The number of shares reported herein consists of the portion of the award that was deemed earned based upon the achievement of the operational target. 100% of the number of shares of common stock reported herein will vest and be delivered in March 2026.↩ 1
- F4
- Includes 82,963 restricted stock units that have not yet vested or been delivered to the Reporting Person.↩ 1
- F5
- Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 24, 2022, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period. The Compensation, Nominating and Governance Committee of the Issuer's Board of Directors determined on March 25, 2026 that certain of the operational targets had been achieved. The number of shares of common stock subject to the stock option as reported herein consists of the portion of the award that was earned based upon the achievement of the operational targets.↩ 1
- F6
- 50% of the portion of the option reported herein will vest and become exercisable in March 2026. 50% of the portion of the option reported herein will vest and become exercisable in December 2026.↩ 1
- F7
- Represents shares of common stock underlying a portion of an award of restricted stock units previously granted by the Issuer on March 22, 2023, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period. The Compensation, Nominating and Governance Committee of the Issuer's Board of Directors determined on March 25, 2026 that certain of the operational targets had been achieved. The number of shares of common stock subject to the stock option as reported herein consists of the portion of the award that was earned based upon the achievement of the operational targets.↩ 1
- F8
- This option was granted on March 25, 2026 and has a four-year vesting schedule in which 25% vests on the first anniversary of the grant date and the remainder vests in equal monthly installments for 36 months thereafter, such that the stock option vests in full on the four-year anniversary of the grant date.↩ 1
Signature 1
- Signed
- Diana Scherer, Attorney-in-Fact
- Date
- 2026-03-27
Company context
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel,